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Abstract: 
Background: In patients with coronary heart disease, being overweight or obese is 
associated with better outcomes, a phenomenon known as the 'obesity paradox'. Despite 
the high prevalence of obesity in the United Sates, its effects on infarct size are largely 
unexplored. 
Methods: Prospective cross-sectional study of 102 consecutive patients admitted with 
acute myocardial infarction (MI). Standardized forms were used to collect data on body 
mass index (BMI), waist circumference (WC), cardiovascular risk factors, and 
medications. Peak troponin I and creatinine phosphokinase (CPK) were used to estimate 
infarct size. Epicardial and pericardial fat were measured by echocardiography. We used 
univariate and multivariate analyses to assess whether obesity was associated with infarct 
size. Correlations between BMI, WC and cardiac fat with cardiac biomarkers were also 
performed.  
Results: Mean age was 62±12 years, and 55% were men. Obesity was diagnosed in 69%. 
On multivariate analysis, obesity was associated with greater infarct size in non-ST 
elevation MI (p=0.02). A positive correlation was observed between BMI and peak 
troponin I (rho=0.24, p=0.03), and both, BMI and WC had a positive correlations with 
CPK levels (rho=0.28, & rho=0.28, both p=0.02). However, in ST elevation MI, obesity 
was associated with smaller infarct size (p=0.05). Epicardial fat + pericardial fat had a 
negative correlation with peak CPK levels (rho=-0.36, p=0.05). 
Conclusions: We observed an opposite association between obesity and infarct size 
depending on the type of MI. These results were unexpected and may provide insight into 
the pathophysiology of the obesity paradox.  (Word count: 244)  
Introduction: 
Obesity has become the epidemic of our time. Studies using body fat to diagnose obesity 
estimate that 1 of every 2 people are obese [1, 2]. Obesity contributes to the development 
of several cardiovascular (CV) risk factors, including hypertension, diabetes, metabolic 
syndrome, dyslipidemia, and obstructive sleep apnea, and may be an independent risk 
factor for coronary heart disease (CHD) [3]. However, large epidemiologic studies have 
shown that, compared to normal weight people, overweight and obese subjects with CV 
diseases, including CHD and following an acute myocardial infarction (MI), have better 
outcomes [4], a phenomenon known as the “obesity paradox” [4-8]. 
 
It is well accepted that cardiac biomarkers reflect myocardial damage. Of the several 
cardiac biomarkers, troponin I best reflects infarct size [9, 10], showing an excellent 
correlation with infarct size, as measured by cardiac magnetic resonance (r=0.84), and 
has independent prognostic value [9-11].  
 
Despite obesity being prevalent in patients with MI, its effects on infarct size are largely 
unexplored. The aim of this study was to examine associations between obesity and 
cardiac fat with infarct size estimated by peak troponin I and creatinine phosphokinase 
(CPK) levels. 
Methods:  
Study design and subject selection 
A prospective cross-sectional study of 102 consecutive patients aged 30 to 89 years who 
were admitted to the coronary care unit from March 2010 to March 2011 with the 
diagnosis of MI was performed. We excluded patients with recent cocaine use, severe 
congestive heart failure (ejection fraction <20%), on hemodialysis, or with severe 
psychiatric conditions (unable to sign consent). Informed consent was obtained from each 
patient and the study protocol conforms to the ethical guidelines of the 1975 Declaration 
of Helsinki as reflected in a priori approval by the Einstein Healthcare Network 
Institutional Review Board. The authors of this manuscript have certified that they 
comply with the Principles of Ethical Publishing in the International Journal of 
Cardiology [12]. 
 
Anthropometric measurements and obesity definition 
Standardized forms were used to collect data on anthropometric variables. Body weight 
was measured with an electronic load cell scale to the nearest 0.01 kg. Height was 
measured to the nearest 0.1 cm using a fixed stadiometer. Waist circumference (WC) was 
determined using a measuring tape positioned at the high point of the iliac crest at the end 
expiration with the tape snug but not compressing the skin. Body mass index (BMI) was 
calculated as weight (kg) divided by height (m
2
). Obesity was defined according to 
American Heart Association as a BMI >30 kg/m
2 
and/or WC >88 cm in women and >102 
cm in men [3]. 
 
Abstraction of clinical data 
Standardized forms and medical records were used to obtain demographics and to 
determine the presence/absence of CV risk factors. Hypertension, diabetes, dyslipidemia, 
history of CHD and congestive heart failure were documented if self-reported by the 
patient or previously recorded on medical records, or if the patients were on medical 
therapy for those conditions. We further collected data on family history of premature 
CHD disease, smoking (current/former) and time of onset of chest pain. Screening for 
sleep apnea was performed by using the modified Berlin questionnaire [13]. Acute MI, 
non-ST elevation MI (NSTEMI), and ST elevation MI (STEMI) were defined according 
to American Heart Association and American College of Cardiology recommendations 
[14]. 
Laboratory data collected included complete blood count, fasting basic metabolic profile, 
fasting lipid profile and cardiac biomarkers (troponin I and CPK). We recorded peak 
troponin I and CPK levels as surrogates of infarct size as previously described [9-11]. At 
the time of admission, medications were recorded, including the use of antihypertensives, 
diuretics, nitrates, antiarrhythmics, diabetes medications, statins or any other lipid 
lowering therapy, antiplatelet and anticoagulation therapy. 
 
Echocardiographic and angiographic data 
Transthoracic Doppler echocardiography was performed and reported according to the 
American Society of Echocardiography guidelines [15]. Cardiac fat, including epicardial 
adipose tissue (EAT), pericardial adipose tissue (PAT) and EAT plus PAT (EAT+PAT) 
were measured by transthoracic echocardiography by a single operator (ARC) averaging 
3 consecutive beats at end-systole in the parasternal long axis view [16]. 
Intraobserver variability was performed by re-measuring 10 randomly selected patients 
one month later (r=0.97, p<0.0001). All measurements were performed blinded to clinical 
data of the patients. Angiographic data, including number of diseased vessels, as well as 
culprit vessel, were obtained from cardiac catheterization reports. 
 
Statistical analyses 
Data are reported as mean ± SD for continuous variables, and number and (%) for 
categorical variables. This study was designed to detect a difference of 4 ng/mL in peak 
troponin I between obese and non-obese subjects with 80% power and a two-tail α=0.05. 
To assess baseline differences by type of MI and obesity status we used Students t-test 
for continuous variables and Chi
2
 or Fishers exact test for categorical variables. We tested 
for normal distribution across the recorded variables, and we used the logarithm of peak 
troponin I and creatinine phosphokinase (CPK) due to the skewness of these continuous 
variables. Non-parametric correlations (Spearman) were performed to establish the 
association between BMI, WC, and cardiac fat with cardiac biomarkers. Due to 
significant difference in the peak troponin and CPK levels between NSTEMI and 
STEMI, analyses were reported separately. Two-tail p-values <0.05 were considered 
significant in advance. We performed univariate analyses to identify predictors of infarct 
size estimated by peak troponin I and CPK levels (p-value for inclusion <0.10). 
Multivariate analyses were performed to identify independent predictors of infarct size 
after adjustment for age, sex, race, traditional cardiovascular risk factors, obstructive 
sleep apnea, ejection fraction, three vessel disease, and time of onset of chest pain (p-
value <0.05). Analyses were performed using JMP version 10.0 (SAS Institute, Cary, 
NC).  
 
Results: 
We enrolled 102 subjects (Table 1) of whom 73 (71.5%) had NSTEMI. Mean age of the 
sample was 61±12 years, and 56 (55%) were men. Sixty-one percent were African 
American, 21% Caucasian, 12% Hispanic, and 6% of other race. Obesity was present in 
69%. Comparing STEMI with NSTEMI (Table 1), those with STEMI were younger 
(58±12 vs. 63±12 years, p=0.05), had a lower prevalence of previously diagnosed CHD 
(14 vs. 45%, p=0.002), congestive heart failure (0 vs. 13%, p=0.04), and more PAT 
(8±3.1 vs. 6.6±2.8mm, p=0.05).  
 
Association between obesity and infarct size in NSTEMI patients 
Baseline characteristics, as well as CV risk factors and cardiac biomarkers between obese 
and non-obese subjects with NSTEMI are shown in Table 2A. Compared to non-obese 
subjects, those with obesity were more likely to be women (70 vs. 42%, p=0.02) and 
diabetic (57 vs. 22%, p=0.004), had a high probability of having obstructive sleep apnea 
(68 vs. 13%, p<0.0001), and had higher peak troponin I (23.6±31 vs. 17.8±37ng/mL, 
p=0.04) and CPK levels (590±549 vs. 334±274U/L, p=0.05) -Figure 1A. 
 
Significant univariate predictors for infarct size estimated by peak troponin I were 
hypertension (p=0.01), obesity (p=0.03) and possibly race (p=0.09), all of which were 
associated with higher troponin I. On multivariate analysis, obesity (p=0.02) remained a 
significant predictor of higher peak troponin I. Hypertension (p=0.01) and obesity 
(p=0.04) were significantly associated with higher peak CPK levels (Table 3A). On 
multivariate analysis both obesity (p=0.02) and hypertension (p=0.02) remained 
significant predictors for higher peak CPK (table 4A). 
 
Correlations between BMI, WC, and cardiac fat with cardiac biomarkers are shown in 
Table 5A.  BMI had a significant positive correlations with peak troponin I (rho=0.24, 
p=0.03) and CPK (rho=0.28, p=0.02), while WC had a significant positive correlation 
with peak CPK (rho=0.24, p=0.05).  
 
Association between obesity and infarct size in STEMI patients 
Baseline characteristics, as well as CV risk factors and cardiac biomarkers between obese 
and non-obese subjects with STEMI are shown in Table 2B. Compared to non-obese 
subjects, those with obesity had more EAT (7.1±2.2 vs. 4.9±1.9mm, p=0.01), and 
EAT+PAT (15.8±3.8 vs. 11.5±4.7mm, p=0.03), and had lower peak troponin I (104±141 
vs. 182±114ng/mL, p=0.02) -Figure 1B. 
 
Significant univariate predictors for infarct size estimated by peak troponin I were age 
(p=0.05) which was associated with higher peak troponin I, while obesity (p=0.06), EAT 
(p=0.05), and EAT+PAT (p=0.07) were associated with lower peak troponin I. On 
multivariate analysis, only obesity (p=0.02) remained as a significant predictor for lower 
peak troponin I. For peak CPK levels, age (p=0.06), history of CHD (p=0.04) and 
diabetes (p=0.06), were significant predictors of higher peak CPK (Table 3B), while 
EAT+PAT (p=0.05) was associated with lower peak CPK. On multivariate analysis none 
of those remained significant, though there was a trend for diabetics (p=0.08) to have 
higher peak CPK (Table 4B). 
 
Correlations between BMI, WC, and cardiac fat with cardiac biomarkers are shown in 
table 5B.  A trend towards a negative correlation was observed between EAT and 
EAT+PAT with peak troponin I (rho=-0.33, p=0.08, and rho=-0.34, p=0.07, 
respectively), while a significant negative correlation was observed between EAT+PAT 
with peak CPK (rho=-0.36, p=0.05). A trend towards a negative correlation was also 
observed between EAT and PAT with peak CPK levels (rho=-0.31, p=0.10, and rho=-
0.34, p=0.06, respectively). 
Discussion: 
The main finding of our study is that obesity has a significant and independent 
association with infarct size at the time of acute MI. Interestingly, obesity was associated 
with greater infarct size in patients with NSTEMI, while in patients with STEMI it was 
associated with smaller infarct size. To our knowledge, this is the first study to report an 
association between cardiac fat and infarct size. We also observed that EAT+PAT is 
associated with smaller infarct size among STEMI patients. 
 
There are only a few small studies that have examined the association of obesity on 
infarct size. Pingitore, et al, performed cardiac magnetic resonances in 89 patients after 
their first MI (at least 3 months old) to assess the extent of MI size. They observed a 
smaller infarct size in obese patients. In should be noted that >80% of their population 
were STEMI, and these findings are similar to our STEMI group [17]. In another study, 
Iglesias Bolanos, et al, studied the association between total and central obesity on infarct 
size in 40 men at the time of MI. Both BMI (r=0.43) and WC (r=0.47) showed a 
significant positive correlation with CPK (measured as AUC) [18]. These correlations are 
similar to our group of NSTEMI patients. It is important to note that Igleasias Bolanos 
study did not distinguished between STEMI and NSTEMI that in our study was noted to 
be an effect-modifier, meaning that obesity had opposite associations with infarct size by 
type of MI, and in fact, the interaction between BMI (but not WC) with peak troponin I 
by type of MI was statistically significant (p=0.005). 
 
Furthermore, we believe this is the first study looking at the association of cardiac fat 
measured by echocardiography with infarct size. We observed that EAT+PAT was 
associated with smaller infarct size in STEMI patients. Much recent work has focused on 
the pathophysiology of cardiac fat in cardiovascular disease, and our findings though 
interesting, need to be replicated in larger studies. 
 
Strengths and limitations 
Strengths of our study include the careful adjustment for potential confounders, including 
obstructive sleep apnea, which is rarely accounted for in obesity studies. In addition, we 
excluded other potential confounders, including patients on hemodialysis and severe 
congestive heart failure.  Limitations of our study include a relatively small sample size, 
especially in the STEMI group (28.5% of MI), which could have limited our power to 
detect other possible associations with infarct size. Another potential limitation is the use 
cardiac biomarkers to estimate infarct size, instead of actually measuring infarct size by 
cardiac magnetic resonance or other novel technologies. However, recent work has 
shown that a single measurement of peak troponin I has an excellent correlation with 
infarct size [9-11].  
 
Conclusions 
We observed significant associations between obesity and infarct size. Interestingly, the 
direction of these associations varied by type of MI. While obesity was associated with 
greater infarct size in NSTEMI patients, obesity was associated with smaller infarct size 
in STEMI. These results were unexpected and may provide insight into the 
pathophysiology of the obesity paradox.   
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Figure legends 
 
Figure 1A. Cardiac biomarkers by obese status in NSTEMI patients. 
Figure shows in the Y axis (log) peak troponin I and (log) peak CPK and in 
the X axis obese vs. non-obese patients with NSTEMI. There is a significant 
difference in cardiac biomarkers with higher levels in the obese group. 
 
Figure 1B. Cardiac biomarkers by obese status in STEMI patients. 
Figure  shows in the Y axis (log) peak troponin I and (log) peak CPK and in 
the X axis obese vs. non-obese patients with STEMI. There is a significant 
difference in cardiac biomarkers with lower levels in the obese group. 
 
 
Table 1 Baseline characteristics for all patients, and by type of AMI 
 
 
Variable  
All 
n = 102 
STEMI 
n = 29 
NSTEMI 
n = 73  
 
+p-value 
Age, years 61.9 ± 12 58 ± 12 63 ± 12 0.05 
Sex, men 56 (55) 19 (65) 37 (51) 0.17 
Race, % 
African-American 
Caucasian 
Hispanic 
Other 
 
62 (61) 
22 (21) 
12 (12) 
6 (6) 
 
18 (62) 
7 (24) 
2 (7) 
2 (7) 
 
44 (60) 
15 (21) 
10 (14) 
4 (5) 
 
 
0.79 
*Obese, % 70 (69) 20 (69) 50 (68) 0.96 
BMI, km/m
2
 30.1 ± 6.7 29.8 ± 6 30.3 ± 7 0.71 
Waist circumference, cm 102 ± 17 102 ± 15 102 ± 18 0.87 
Epicardial Fat, mm 6.2 ± 2.2 6.4 ± 2.3 6.1 ± 2.2 0.52 
Pericardial Fat, mm 7.0 ± 2.9 8.0 ± 3.1 6.6 ± 2.8 0.05 
Epicardial + Pericardial  Fat, mm 13.2 ± 4.6 14.4 ± 4.5 12.7 ± 4.5 0.10 
Hypertension, % 94 (93) 27 (93) 67 (93) 0.99 
Diabetes, % 43 (43) 10 (34) 33 (46) 0.29 
Dyslipidemia, % 81 (80) 20 (69) 72 (85) 0.07 
Smoking, % 47 (47) 12 (41) 35 (48) 0.50 
Family history of coronary disease, % 52 (51) 14 (48) 38 (52) 0.73 
History of coronary artery disease, % 37 (36) 4 (14) 33 (45) 0.002 
Congestive heart failure, % 9 (9) 0 (0) 9 (13) 0.04 
Obstructive sleep apnea, % 55 (54) 18 (62) 37 (51) 0.29 
Ejection fraction, % 45 ± 12 44.6 ± 12 45.4 ± 12 0.78 
Onset of chest pain to peak enzyme, 
hrs. 
16.7 ± 16 12 ± 4.6 18 ± 19 0.007 
Triple vessel disease^, %  33 (34) 6 (21) 27 (39) 0.09 
Creatinine, mg/dL 1.3 ± 0.4 1.39 ± 0.4 1.25 ± 0.4  0.18 
+Peak troponin I, ng/mL 50.9 ± 90 128 ± 136 20 ± 28 <0.0001 
+Peak creatinine phosphokinase, U/L 954 ± 1263 2017 ± 181 510 ± 492 <0.0001 
 
* BMI >30kg/m
2
 and/or waist circumference >88cm for women and >102cm for men 
** Comparison for STEMI vs. NSTEMI 
^ 98 patients with angiographic results 
+ Logarithm of peak troponin I and CPK was used to estimate p-values 
Table 2A: Characteristics in obese vs. non-obese subjects with NSTEMI  
 
 
 
Variable n = 73 
*Obese 
n = 50 
Non-Obese 
n = 23 
 
p-value 
Age, years 61.8 ± 12.8 67.1 ± 12 0.08 
Sex, men 21 (42) 16 (70) 0.02 
Race, % 
African-American 
Caucasian 
Hispanic 
Other 
 
32 (64) 
9 (18) 
8 (16) 
1 (2) 
 
12 (52) 
6 (26) 
2 (9) 
3 (13) 
 
 
0.25 
BMI, km/m
2
 33.1 ± 6.4 24.3 ± 3.5 <0.0001 
Waist circumference, cm 110 ± 15 85 ± 10 <0.0001 
Epicardial Fat, mm 6.1 ± 2.2 5.9 ± 2.3 0.76 
Pericardial Fat, mm 6.7 ± 3.0 6.3 ± 2.4 0.57 
Epicardial + Pericardial  Fat, mm 12.9 ± 4.7 12.3 ± 4.4 0.62 
Hypertension, % 47 (96) 20 (87) 0.16 
Diabetes, % 28 (57) 5 (22) 0.004 
Dyslipidemia, % 41 (82) 20 (91) 0.31 
Smoking, % 23 (47) 12 (52) 0.67 
Family history of coronary disease, % 29 (58) 9 (39) 013 
History of coronary artery disease, % 23 (46) 10 (43) 0.84 
Congestive heart failure, % 4 (8) 5 (23) 0.08 
Obstructive sleep apnea, % 34 (68) 3 (13) <0.0001 
Ejection fraction, % 46.8 ± 11 42.1 ± 14 0.20 
Onset of chest pain to peak enzyme, hrs. 20.1 ± 16 15.3 ± 23 0.38 
Triple vessel disease^, %  20 (43) 7 (30) 0.29 
Creatinine, mg/dL 1.2 ± 0.4 1.2 ± 0.4 0.94 
+Peak troponin I, ng/mL 23.6 ± 31 17.8 ± 37  0.04 
+Peak creatinine phosphokinase, U/L 590 ± 549 334 ± 274 0.05 
 
* BMI >30kg/m
2
 and/or waist circumference >88cm for women and >102cm for men 
^ 70 patients with angiographic results 
+ Logarithm of peak troponin I and CPK was used to estimate p-values 
Table 2B Characteristics in obese vs. non-obese subjects with STEMI  
 
 
 
Variable n = 29 
*Obese 
n = 20 
Non-Obese 
n = 9 
 
p-value 
Age, years 59.3 ± 13 55.6 ± 9 0.41 
Sex, men 12 (60) 7 (78) 0.35 
Race, % 
African-American 
Caucasian 
Hispanic 
Other 
 
13 (65) 
5 (25) 
2 (10) 
0 (0) 
 
5 (56) 
2 (22) 
0 (0) 
2 (22) 
 
 
0.14 
BMI, km/m
2
 32.6 ± 4.9 23.5 ± 3.2 <0.0001 
Waist circumference, cm 109 ± 12   86 ± 9.7 <0.0001 
Epicardial Fat, mm 7.1 ± 2.2 4.9 ± 1.9 0.01 
Pericardial Fat, mm 8.6 ± 3 6.6 ± 3.1 0.12 
Epicardial + Pericardial  Fat, mm 15.8 ± 3.8 11.5 ± 4.7  0.03 
Hypertension, % 19 (95) 8 (89) 0.54 
Diabetes, % 7 (35) 3 (33) 0.93 
Dyslipidemia, % 15 (75) 5 (26) 0.29 
Smoking, % 6 (30) 6 (67) 0.06 
Family history of coronary disease, % 11 (55) 3 (33) 0.28 
History of coronary artery disease, % 2 (10) 2 (22) 0.37 
Congestive heart failure, % 0 (0) 0 (0) - 
Obstructive sleep apnea, % 14 (70) 4 (44) 0.18 
Ejection fraction, % 47 ± 11 39 ± 12 0.15 
Onset of chest pain to peak enzyme, hrs. 12.4 ± 4.6 11.2 ± 4.8 0.55 
Triple vessel disease^, %  3 (16) 3 (33) 0.29 
Creatinine, mg/dL 1.3 ± 0.3 1.4 ± 0.7 0.62 
+Peak troponin I, ng/mL 104 ± 141 182 ± 114 0.02 
+Peak creatinine phosphokinase, U/L 1723 ± 1776 2636 ± 1848 0.17 
 
* BMI >30kg/m
2
 and/or waist circumference >88cm for women and >102cm for men 
^ 28 patients with angiographic results 
+ Logarithm of peak troponin I and CPK was used to estimate p-values
Table 3A Univariate predictors of peak troponin I and CPK levels in 
NSTEMI 
 
 
Variable for peak troponin I 
 
F-ratio 
 
p-value 
Hypertension 6.00 0.017 
*Obesity 4.59 0.035 
Race 2.91 0.092 
 
Variable for peak CPK 
 
F-ratio 
 
p-value 
Hypertension 6.97 0.010 
*Obesity 4.13 0.046 
 
* BMI >30kg/m
2
 and/or waist circumference >88cm for women and >102cm for men 
 
 
Table 3B Univariate predictors of peak troponin I and CPK levels in 
STEMI 
 
 
Variable for peak troponin I 
 
F-ratio 
 
p-value 
Epicardial + Pericardial  Fat -4.02 0.055 
Age 3.92 0.057 
*Obesity -3.66 0.066 
Epicardial fat -3.43 0.075 
 
Variable for peak CPK 
 
F-ratio 
 
p-value 
History of coronary artery disease 4.36 0.047 
Epicardial + Pericardial  Fat -3.94 0.058 
Diabetes 3.77 0.063 
Age 3.47 0.074 
 
* BMI >30kg/m
2
 and/or waist circumference >88cm for women and >102cm for men 
 
Table 4A Multivariate predictors of peak troponin I and CPK levels in 
NSTEMI 
 
 
Variable for peak troponin I 
 
F-ratio 
 
p-value 
*Obesity 5.43 0.023 
Hypertension 2.96 0.091 
 
Variable for peak CPK 
 
F-ratio 
 
p-value 
Hypertension 5.42 0.024 
*Obesity 5.38 0.024 
 
* BMI >30kg/m
2
 and/or waist circumference >88cm for women and >102cm for men 
 
 
Table 4B Multivariate predictors of peak troponin I and CPK levels in STEMI 
 
 
Variable for peak troponin I 
 
F-ratio 
 
p-value 
*Obesity -4.47 0.054 
 
Variable for peak CPK 
 
F-ratio 
 
p-value 
Diabetes 3.48 0.086 
 
* BMI >30kg/m
2
 and/or waist circumference >88cm for women and >102cm for men 
 
Multivariate analyses adjusted for: Age, sex, race, hypertension, diabetes, dyslipidemia, 
smoking, history of coronary disease, congestive heart failure, obstructive sleep apnea, 
triple vessel disease and time of onset of chest pain.
Table 5A Correlations between BMI, waist circumference, epicardial 
fat, pericardial fat and epicardial + pericardial fat with peak troponin I 
and CPK in patients with NSTEMI 
 
 
 Peak Troponin I Peak CPK 
BMI 0.24, p=0.03 0.28, p=0.02 
Waist circumference 0.12, p=NS 0.24, p=0.05 
Epicardial Fat 0.08, p=NS 0.04. p=NS 
Pericardial Fat -0.06, p=NS -0.07, p=NS 
Epicardial and Pericardial Fat 0.01, p=NS -0.03, p=NS 
 
NS = p-value >0.10 
 
 
Table 5B Correlations between BMI, waist circumference, epicardial 
fat, pericardial fat and epicardial + pericardial fat with peak troponin I 
and CPK in patients with STEMI 
 
 
 Peak Troponin I Peak CPK 
BMI -0.25, p=NS -0.18, p=NS 
Waist circumference -0.05, p=NS -0.02, p=NS 
Epicardial Fat -0.33, p=0.08 -0.31, p=0.10 
Pericardial Fat -0.29, p=NS -0.34, p=0.06 
Epicardial and Pericardial Fat -0.34, p=0.07 -0.36, p=0.05 
 
NS = p-value >0.10 
 
 
 
 
 
